ZBH ZIMMER BIOMET HOLDINGS INC.

ZBH SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of Commencement of a Class Action Involving Zimmer Biomet Holdings, Inc. and a Lead Plaintiff Deadline of January 31, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of Indiana on behalf of investors who purchased Zimmer Biomet Holdings, Inc. (NYSE:ZBH) securities between September 7, 2016 and October 31, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/zimmer-biomet-holdings. There is no cost or obligation to you.

According to the complaint, during the Class Period, defendants issued materially false and/or misleading statements and/or failed to disclose: 1) issues within the supply chain caused a decline in order fulfillment, particularly within the knee and hip portfolios; 2) as such, Zimmer Biomet would not realize its revenues and profit as expected and; 3) as a result of the above, the Company’s statements regarding its business, operations and prospects, were false and misleading and/or lacked a reasonable basis.

If you suffered a loss in Zimmer Biomet you have until January 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/zimmer-biomet-holdings.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
03/01/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZIMMER BIOMET HOLDINGS INC.

Zimmer Biomet Holdings, Inc.: Update to credit analysis

Our credit view of this issuer reflects its healthy EBITDA margin and strong free cash flow generation, constrained by its pricing pressure from competition.

Moody's Ratings affirms Zimmer Biomet's Baa2 senior unsecured rating; ...

Moody's Ratings (Moody's) affirmed the senior unsecured ratings of Zimmer Biomet Holdings, Inc. ("Zimmer Biomet") at Baa2. The outlook is stable. The ratings affirmation reflects solid operating performance due to strong demand and operational improvements that have contributed to solid organic gr...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Zimmer Biomet Holdings, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 March 2025 in which we reassessed the appropriateness of the ratings in the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch